Research programme: hepatitis C virus protease inhibitors - InterMune

Drug Profile

Research programme: hepatitis C virus protease inhibitors - InterMune

Alternative Names: ITMN A; ITMN-5489; Second-generation HCV protease inhibitors - InterMune

Latest Information Update: 13 Feb 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Array BioPharma; InterMune
  • Developer InterMune; Roche
  • Class Small molecules
  • Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 30 Jun 2011 Discontinued - Preclinical for Hepatitis C in USA (PO)
  • 13 Apr 2010 Preclinical development is ongoing in USA
  • 25 Apr 2009 Preclinical pharmacodynamics and pharmacokinetics data presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top